These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17611295)

  • 1. Validation of a viral and bacterial inactivation step during the extraction and purification process of porcine collagen.
    Forest P; Morfin F; Bergeron E; Dore J; Bensa S; Wittmann C; Picot S; Renaud FN; Freney J; Gagnieu C
    Biomed Mater Eng; 2007; 17(4):199-208. PubMed ID: 17611295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation kinetics of model and relevant blood-borne viruses by treatment with sodium hydroxide and heat.
    Borovec S; Broumis C; Adcock W; Fang R; Uren E
    Biologicals; 1998 Sep; 26(3):237-44. PubMed ID: 10208725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virus safety of a porcine-derived medical device: evaluation of a viral inactivation method.
    Hodde J; Hiles M
    Biotechnol Bioeng; 2002 Jul; 79(2):211-6. PubMed ID: 12115437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of virus in intravenous immunoglobulin G using solvent/detergent treatment and pasteurization.
    Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Sharifi Z
    Hum Antibodies; 2008; 17(3-4):79-84. PubMed ID: 19029665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virus inactivation by protein denaturants used in affinity chromatography.
    Roberts PL; Lloyd D
    Biologicals; 2007 Oct; 35(4):343-7. PubMed ID: 17517521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
    Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
    J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance of surface-dried virus to common disinfection procedures.
    Terpstra FG; van den Blink AE; Bos LM; Boots AG; Brinkhuis FH; Gijsen E; van Remmerden Y; Schuitemaker H; van 't Wout AB
    J Hosp Infect; 2007 Aug; 66(4):332-8. PubMed ID: 17601636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of model virus removal and inactivation capacity of an erythropoietin purification process.
    Pérez M; Rodríguez E; Rodríguez M; Paez R; Ruibal I; Noa E; García O; Moya G; Martínez M; Marcelo J; Martínez A; Dubal M; Navea L; Valdés R
    Biologicals; 2011 Nov; 39(6):430-7. PubMed ID: 21982851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Validation of the virus inactivation capacity of a procedure of human plasma albumin purification by chromatography].
    Stoltz JF; Geschier C; Rivat C; Sertillanges P; Grandgeorges M; Liautaud J; Regnault V; Dumont L
    Ann Pharm Fr; 1993; 51(2):78-93. PubMed ID: 8250488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of spiked porcine circovirus during the manufacture of a Vero cell-derived vaccine.
    Lackner C; Leydold SM; Modrof J; Farcet MR; Grillberger L; Schäfer B; Anderle H; Kreil TR
    Vaccine; 2014 Apr; 32(18):2056-61. PubMed ID: 24560672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fast, broad-range disinfection of bacteria, fungi, viruses and prions.
    Beekes M; Lemmer K; Thomzig A; Joncic M; Tintelnot K; Mielke M
    J Gen Virol; 2010 Feb; 91(Pt 2):580-9. PubMed ID: 19864502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential sensitivities of pathogens in red cell concentrates to Tri-P(4)-photoinactivation.
    Trannoy LL; Terpstra FG; de Korte D; Lagerberg JW; Verhoeven AJ; Brand A; van Engelenburg FA
    Vox Sang; 2006 Aug; 91(2):111-8. PubMed ID: 16907871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
    Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
    Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of virus safety of an antihemophilc factor IX by virus filtration process.
    Kim IS; Choi YW; Kang Y; Sung HM; Sohn KW; Kim YS
    J Microbiol Biotechnol; 2008 Jul; 18(7):1317-25. PubMed ID: 18667862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of adenovirus type 5 by caustics.
    Jannat R; Hsu D; Maheshwari G
    Biotechnol Prog; 2005; 21(2):446-50. PubMed ID: 15801784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of betapropiolactone (BPL) as an inactivant for infectious bovine rhinotracheitis (IBR) virus.
    Kamaraj G; Lakshmi Narasu M; Srinivasan VA
    Res Vet Sci; 2008 Dec; 85(3):589-94. PubMed ID: 18262212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of viral inactivation of pseudorabies virus, encephalomyocarditis virus, bovine viral diarrhea virus and porcine parvovirus in pancreatin of porcine origin.
    Caruso C; Gobbi E; Biosa T; Andra' M; Cavallazzi U; Masoero L
    J Virol Methods; 2014 Nov; 208():79-84. PubMed ID: 25110118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virus reduction in an intravenous immunoglobulin by solvent/detergent treatment, ion-exchange chromatography and terminal low pH incubation.
    Roberts PL; Dunkerley C; Walker C
    Biologicals; 2012 Sep; 40(5):345-52. PubMed ID: 22658506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral safety characteristics of Flebogamma DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nanofiltered intravenous immunoglobulin.
    Caballero S; Nieto S; Gajardo R; Jorquera JI
    Biologicals; 2010 Jul; 38(4):486-93. PubMed ID: 20350815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a novel, rapid-acting, sterilizing solution at room temperature.
    Hobson DW; Seal LA
    Am J Infect Control; 2000 Oct; 28(5):370-5. PubMed ID: 11029137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.